Immune checkpoint inhibitors and cancer vaccines are currently attracting a lot of attention as novel cancer treatment strategies. In order to achieve sufficient anti-tumor effects using these treatments, target tumor cells need to express HLA class I antigens. It is important to evaluate the expression of HLA class I antigens in tumor cells in order to establish treatment methods. This product is an antibody that recognizes human HLA-A,B,C. Because it can be used for immunostaining, it is useful for evaluating the expression of HLA class I in tumor cells and tissues.
Analysis of reactivity using recombinant MHC class I heavy chain extracellular domain
Analysis of HLA class I expression in oral cavity cancer cell line, OSC20
Lane 1: Oral cavity cancer cell line OSC20
Lane 2: OSC20-A*24:02 (HLA-A*24:02 transfectant)
Lane 3: K562
Lane 4: Recombinant HLA-A*24:02
Data was kindly provided by Dr. Toshihiko Torigoe
(The Department of Pathology, Sapporo Medical University School of Medicine).
HLA class I expression is observed in stromal cells, normal epithelial cells, infiltrating lymphocytes and macrophages. However, it is hardly observed on cancer cells (cytokeratin positive). HLA-DR is expressed on monocytes and macrophages.
Tissue：Head and neck cancer
Orange：HLA class I (Code No. D370-3H)
Red：HLA-DR (clone LN-3)
Blue：Cytokeratin (clone AE1/AE3)
Data was kindly provided by Dr. Susumu Suzuki (Aichi Medical University of Medicine).
Important Cookies information – this message will only appear once